By contrast, in the control groups, only 5 of 139 (3.6%) of the pediatric neurologic controls had GluD2 antibodies (Rasmussen encephalitis 2/23, new-onset epilepsy 0/78, autoimmune encephalitis 3/38; p < 0.0001, Fisher exact test) (data available from Dryad, table 3, doi.org/10.5061/dryad.tq61224). This evidence concerns the gene GLUD2 and autoimmune encephalitis.